Jong-Sup Bae

This inventor holds 5 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Kyungpook National University Industry-Academic Cooperation Foundation, Arez Co., Ltd., Korea Institute of Science and Technology. Active years: 2018-2026.

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 80.0

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

4 out of 363

Kyungpook National University Industry-Academic Cooperation Foundation

Korea Institute of Science and Technology

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673959 - Polysubstituted imidazolo[4,5-c][1,2]thiazine derivative and use thereof (2026-07-07),

2. 12370205 - Composition for preventing or treating fine dust-induced respiratory disease comprising mixture (RGX-365) comprising ginsenosides RG2, RG4, RG6 and RH1, as active ingredient, and preparation method thereof (2025-07-29),

3. 11638741 - Composition for treating cancer or inhibiting cancer metastasis, including TFG or TFMG nanoparticles (2023-05-02),

4. 10513545 - Fusion polypeptide in which anti-inflammatory polypeptide and ferritin monomer fragment are bound and pharmaceutical composition for preventing and treating inflammatory diseases, containing same as active ingredient (2019-12-24),

5. 9932355 - 2,5,6,7-tetrasubstituted thiazolo[4,5-b]pyridine derivatives and use thereof (2018-04-03),

Title: Innovations and Contributions of Inventor Jong-Sup Bae

Introduction

Jong-Sup Bae is a notable inventor based in Daegu, South Korea. He has made significant contributions to the fields of health and medicine, particularly in the development of compositions aimed at treating respiratory diseases and cancer. With a total of 5 patents to his name, Bae's work reflects a commitment to addressing critical health challenges.

Latest Patents

One of Jong-Sup Bae's latest patents is a composition for preventing or treating fine dust-induced respiratory disease. This composition, known as RGX-365, includes a mixture of ginsenosides RG2, RG4, RG6, and RH1 as active ingredients. The invention demonstrates remarkable effects on reducing permeability, reactive oxygen species generation, leucocyte count, and cytokine generation in models of fine dust-induced inflammatory responses. This innovation holds promise for preventing and treating respiratory diseases caused by fine dust exposure.

Another significant patent involves a composition for treating cancer or inhibiting cancer metastasis, which includes TFG or TFMG nanoparticles. This invention aims to normalize blood vessels within tumors, thereby exhibiting effects that can treat cancer and inhibit its metastasis. Bae's research in this area highlights the potential for innovative treatments in oncology.

Career Highlights

Jong-Sup Bae has worked with esteemed institutions such as the Kyungpook National University Industry-Academic Cooperation Foundation and the Korea Institute of Science and Technology. His experience in these organizations has contributed to his expertise in developing health-related innovations.

Collaborations

Throughout his career, Bae has collaborated with notable colleagues, including In-San Kim and Won Hwa Lee. These partnerships have likely enhanced the scope and impact of his research.

Conclusion

Jong-Sup Bae's contributions to the fields of respiratory health and cancer treatment through his innovative patents demonstrate his dedication to improving public health. His work continues to inspire advancements in medical science and technology.